Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotypes

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 10, 2017, Pages 3409-3421

  Al Bachari, Sarah ^a,b,c   Vidyasagar, Rishma ^b,d,e   Emsley, Hedley CA ^b,f   Parkes, Laura M ^b  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

arterial spin labelling; cerebral blood flow; cerebrovascular disease; Magnetic resonance imaging; Parkinson s disease

Indexed keywords

AGED; ARTERIAL SPIN LABELING; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GAIT DISORDER; GLOBUS PALLIDUS; HUMAN; INFERIOR PARIETAL LOBULE; MAJOR CLINICAL STUDY; MALE; MIDDLE TEMPORAL GYRUS; MONTREAL COGNITIVE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PERFUSION; PHENOTYPE; PRIORITY JOURNAL; SUPERIOR TEMPORAL GYRUS; TREMOR; WHITE MATTER LESION; BRAIN CIRCULATION; CEREBROVASCULAR DISEASE; DIAGNOSTIC IMAGING; MIDDLE AGED; NEUROVASCULAR COUPLING; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; WHITE MATTER;

SPIN LABEL;

AGED; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROVASCULAR COUPLING; PARKINSON DISEASE; PHENOTYPE; SPIN LABELS; WHITE MATTER;

EID: 85021241284     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16688919     Document Type: Article

References (51)

1. Bourdenx M, Dovero S, Engeln M, Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun 2015; 3: 46.
2. Collins LM, Toulouse A, Connor TJ, Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012; 62: 2154–2168.
3. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011; 13: e19.
4. Nelson AR, Sweeney MD, Sagare AP, Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim Biophys Acta 2016; 1862: 887–900.
5. Sagare AP, Bell RD, Zlokovic BV. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a011452.
6. Zhao Z, Nelson AR, Betsholtz C, Establishment and dysfunction of the blood-brain barrier. Cell 2015; 163: 1064–1078.
7. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178–201.
8. Nanhoe-Mahabier W, de Laat KF, Visser JE, Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 2009; 5: 533–541.
9. Patel M, Coutinho C, Emsley HC. Prevalence of radiological and clinical cerebrovascular disease in idiopathic Parkinson’s disease. Clin Neurol Neurosurg 2011; 113: 830–834.
10. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014; 71: 499–504.
11. Wang J, Alsop DC, Song HK, Arterial transit time imaging with flow encoding arterial spin tagging (FEAST). Magn Reson Med 2003; 50: 599–607.
12. Zappe AC, Reichold J, Burger C, Quantification of cerebral blood flow in nonhuman primates using arterial spin labeling and a two-compartment model. Magn Reson Imaging 2007; 25: 775–783.
13. Fernandez-Seara MA, Mengual E, Vidorreta M, Cortical hypoperfusion in Parkinson’s disease assessed using arterial spin labeled perfusion MRI. NeuroImage 2012; 59: 2743–2750.
14. Melzer TR, Watts R, MacAskill MR, Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain 2011; 134: 845–855.
15. Borghammer P. Perfusion and metabolism imaging studies in Parkinson’s disease. Dan Med J 2012; 59: B4466.
16. Hendrikse J, Petersen ET, van Laar PJ, Cerebral border zones between distal end branches of intracranial arteries: MR imaging. Radiology 2008; 246: 572–580.
17. Petersen ET, Zimine I, Ho YC, Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques. Br J Radiol 2006; 79: 688–701.
18. Derdeyn CP, Videen TO, Yundt KD, Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain 2002; 125: 595–607.
19. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 2001; 64: 575–611.
20. Al-Bachari S, Parkes LM, Vidyasagar R, Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson’s disease. Neuroimage Clin 2014; 6: 1–8.
21. Emre M, Aarsland D, Brown R, Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–1707.
22. Jankovic J, McDermott M, Carter J, Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529–1534.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
24. Tomlinson CL, Stowe R, Patel S, Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25: 2649–2653.
25. Gunther M, Bock M, Schad LR. Arterial spin labeling in combination with a look-locker sampling strategy: inflow turbo-sampling EPI-FAIR (ITS-FAIR). Magn Reson Med 2001; 46: 974–984.
26. Edelman RR, Siewert B, Darby DG, Qualitative mapping of cerebral blood flow and functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. Radiology 1994; 192: 513–520.
27. Johnson NA, Jahng GH, Weiner MW, Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851–859.
28. Fazekas F, Kleinert R, Offenbacher H, Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43: 1683–1689.
29. Wahlund LO, Barkhof F, Fazekas F, A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318–1322.
30. Schmidt P, Gaser C, Arsic M, An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. NeuroImage 2012; 59: 3774–3783.
31. Leonards CO, Ipsen N, Malzahn U, White matter lesion severity in mild acute ischemic stroke patients and functional outcome after 1 year. Stroke 2012; 43: 3046–3051.
32. Chalela JA, Alsop DC, Gonzalez-Atavales JB, Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000; 31: 680–687.
33. MacIntosh BJ, Lindsay AC, Kylintireas I, Multiple inflow pulsed arterial spin-labeling reveals delays in the arterial arrival time in minor stroke and transient ischemic attack. Am J Neuroradiol 2010; 31: 1892–1894.
34. Wolf ME, Layer V, Gregori J, Assessment of perfusion deficits in ischemic stroke using 3D-GRASE arterial spin labeling magnetic resonance imaging with multiple inflow times. J Neuroimaging 2014; 24: 453–459.
35. Zaharchuk G. Arterial spin label imaging of acute ischemic stroke and transient ischemic attack. Neuroimaging Clin N Am 2011; 21: 285–301.
36. Liu Y, Zhu X, Feinberg D, Arterial spin labeling MRI study of age and gender effects on brain perfusion hemodynamics. Magn Reson Med 2012; 68: 912–922.
37. MacIntosh BJ, Swardfager W, Robertson AD, Regional cerebral arterial transit time hemodynamics correlate with vascular risk factors and cognitive function in men with coronary artery disease. AJNR Am J Neuroradiol 2015; 36: 295–301.
38. Paling D, Thade Petersen E, Tozer DJ, Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability. J Cereb Blood Flow Metab 2014; 34: 34–42.
39. Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 1999; 30: 115–124.
40. Kamagata K, Motoi Y, Hori M, Posterior hypoperfusion in Parkinson’s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 2011; 33: 803–807.
41. Nobili F, Arnaldi D, Campus C, Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging 2011; 38: 2209–2218.
42. Mure H, Hirano S, Tang CC, Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects. NeuroImage 2011; 54: 1244–1253.
43. Huang C, Tang C, Feigin A, Changes in network activity with the progression of Parkinson’s disease. Brain 2007; 130: 1834–46.
44. Hirano S, Asanuma K, Ma Y, Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci 2008; 28: 4201–4209.
45. Leenders KL, Wolfson L, Gibbs JM, The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. Brain 1985; 108: 171–191.
46. Okonkwo OC, Xu G, Oh JM, Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer’s disease. Cereb Cortex 2014; 24: 978–988.
47. Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. J Alzheimers Dis 2014; 42: S411–419.
48. Borghammer P, Cumming P, Østergaard K, Cerebral oxygen metabolism in patients with early Parkinson’s disease. J Neurol Sci 2012; 313: 123–128.
49. Lin WC, Chen PC, Huang YC, Dopaminergic therapy modulates cortical perfusion in Parkinson Disease with and without dementia according to arterial spin labeled perfusion magnetic resonance imaging. Medicine (Baltimore) 2016; 95: e2206.
50. Janelidze S, Lindqvist D, Francardo V, Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 2015; 85: 1834–1842.
51. Yang P, Pavlovic D, Waldvogel H, String vessel formation is increased in the brain of Parkinson Disease. J Parkinsons Dis 2015; 5: 821–836.